Articles from Zonsen PepLib Biotech Inc.

Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered a global research and development (R&D) collaboration and license agreement with Eli Lilly and Company ("Lilly"). Under the agreement, both parties will jointly advance the development of novel peptide-based drug candidates leveraging PepLib’s robust and diverse proprietary peptide libraries and discovery technology platforms.

Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based asset in the field of radioligand therapies (RLTs). Under the agreement, Novartis has obtained an exclusive worldwide license and will be responsible for the development and commercialization activities for the asset.